Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enamine and Exquiron Announces Multiyear Collaboration

Published: Monday, June 03, 2013
Last Updated: Monday, June 03, 2013
Bookmark and Share
Enamine provides Exquiron with large novel diverse screening compound library.

Enamine Ltd and Exquiron Biotech AG have announced a multiyear collaboration under which Enamine will provide a carefully selected, novel diverse screening compound library.

This library will be made available by Exquiron to screening clients for hit discovery projects.

The library provided by Enamine is a great asset for discovery programs as it includes a high number of diverse drug-like compounds.

Exquiron and its clients will also have access to Enamine’s full range of chemistry expertise, for post screening follow-up.

Dr. Serge Parel, VP Chemistry and Research Informatics, Exquiron, commented: “Offering high quality chemistry to our clients is crucial. We are impressed by the quality and novelty of Enamine’s compounds, coupled with their logistics and support services. Together we can offer clients excellent value.”

“We are pleased that Exquiron has chosen to work with us. We see this as confirmation of the quality of our chemistry and services, and hope that our collaboration will contribute to Exquiron’s success,” added Michael Bossert, Head of Strategic Alliances, Enamine.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Enamine Announces Extension of Collaboration with Sanofi in Early Drug Discovery
Sanofi continue to access Enamine’s in-house designed and synthesized screening compound library.
Friday, December 19, 2014
Enamine Provides Large Novel Diverse Compound Screening Library To BioFocus
The company announced it has extended its long-standing relationship with BioFocus. The library will be available to BioFocus HTS collaborators in early 2012.
Wednesday, February 01, 2012
Scientific News
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Molecular ‘Kiss Of Death’ Flags Pathogens For Destruction
Researchers have discovered that our bodies mark pathogen-containing vacuoles for destruction by using a molecule called ubiquitin, commonly known as the "kiss of death."
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos